Alkermes (ALKS)
(Real Time Quote from BATS)
$26.80 USD
-0.57 (-2.08%)
Updated Sep 25, 2024 12:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
ALKS 26.80 -0.57(-2.08%)
Will ALKS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Alkermes (ALKS) is a Strong Value Stock
Here's Why Alkermes (ALKS) is a Strong Value Stock
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
Other News for ALKS
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference
IHF: Healthcare Dashboard For September
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)